Trial Profile

Phase Ib Trial of the Combination of PI3K Inhibitor BAY80-6946 and Allosteric-MEK Inhibitor BAY86-9766 in Subjects With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Copanlisib (Primary) ; Refametinib (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Bayer

Most Recent Events

20 Apr 2020 Results published in the Targeted Oncology
02 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
25 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com